Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’

T.K. Choueiri (1) , J. Larkin (2) , S. Pal (3) , R.J. Motzer (4) , B.I. Rini (5) , B. Venugopal (6) , B. Alekseev (7) , H. Miyake (8) , Gwenaelle Gravis (9, 10) , M.A. Bilen (11) , S. Hariharan (12) , A. Chudnovsky (13) , K.A. Ching , X.J. Mu , M. Mariani , P.B. Robbins , B. Huang (14) , A. Di Pietro , L. Albiges (15, 16)

1 BWH - Brigham & Women’s Hospital [Boston]
2 Royal Marsden NHS Foundation Trust
3 City of Hope Comprehensive Cancer Center [Duarte]
4 Memorial Sloane Kettering Cancer Center [New York]
5 Vanderbilt University Medical Center [Nashville]
6 University of Glasgow
7 P. Hertsen Moscow Oncology Research Institute
8 Hamamatsu University School of Medicine
9 CRCM - Centre de Recherche en Cancérologie de Marseille
10 Institut Paoli-Calmettes
11 Emory University [Atlanta, GA]
12 Pfizer, Inc [Pearl River, New-York]
13 Pfizer Global Research and Development [Cambridge, MA, USA]
14 Pfizer Worldwide Research and Development [Groton, CT, USA]
15 IGR - Institut Gustave Roussy
16 Département de médecine oncologique [Gustave Roussy]

No abstract available

Domains: Life Sciences [q-bio]; Cancer

T.K. Choueiri, J. Larkin, S. Pal, R.J. Motzer, B.I. Rini, et al.. Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’. ESMO Open, 2021, 6 (4), pp.100177. ⟨10.1016/j.esmoop.2021.100177⟩. ⟨hal-03623494⟩